Overview

• The 78-page blueprint commits over £2 billion to make the UK Europe’s leading life sciences economy by 2030 and the world’s third by 2035.
• Six headline actions include a £600 million Health Data Research Service with the Wellcome Trust, trial approvals slashed to under 150 days, and £520 million for domestic manufacturing.
• Four metrics will track success: commercial R&D and scale-up investment, number of companies valued above £10 billion, FTSE 350 listings, and initial public offerings.
• Trade bodies and pharmaceutical executives commend new data and trial infrastructure but caution that NHS rebate rates of 23.5 – 35.6% under the Voluntary Scheme for Branded Medicines must be reduced to attract innovation.
• Negotiations over those rebate terms are ongoing and the government has not yet released detailed timelines for rolling out the plan’s measures.